Richard Daniels has 30+ years of experience in the pharmaceutical industry spanning all phases of drug development and commercialization. He is currently Managing Director at Halloran Consulting, which provides preclinical, clinical, regulatory and quality services to the life sciences industry. Prior to Halloran, he was the Chief Operating Officer of Primmune Therapeutics. Prior to joining Primmune, Mr. Daniels was Senior Vice President of R&D Planning and Clinical Operations at Intercept Pharmaceuticals. Prior to Intercept, Mr. Daniels spent 15 years at Amgen in increasing roles of responsibility, including the last five years as Executive Director, Oncology Therapeutic Area Lead and a member of the Franchise Strategy Committee responsible for developing Amgen’s oncology strategy and managing the development, registration, and life-cycle activities of Amgen’s portfolio of pipeline and marketed assets. Earlier in Mr. Daniels’ career, he held various scientific positions in discovery, preclinical, and clinical research in both oncology and infectious diseases at Agouron Pharmaceuticals (acquired by Pfizer). Mr. Daniels earned a B.S. in microbiology from the UC San Diego.
Richard Daniels
